It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The ...

As GLP-1 weight loss drugs fly off shelves, Kourtney Kardashian Barker is getting in on the hustle — well, sort of. As ...

For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 ...

Among patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...

Most trillion-dollar companies today are in the technology sector, but one particular healthcare stock is knocking on the ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 584.52% and ...

These once-sizable artificial intelligence (AI) holdings for Google parent Alphabet have been paired down big-time over the ...

French researchers have developed a new drug delivery system that could cut the dosing schedule for the type 2 diabetes and ...

Amycretin mimics the actions of glucagon-like peptide-1 (GLP-1) and amylin, hormones that play a role in reducing blood sugar ...

Medicare may cover Wegovy for adults with cardiovascular disease and either obesity or overweight. Learn more about Medicare ...

to examine potential applications of glucagon-like peptide-1 receptor (GLP-1R) agonists in central nervous system disorders, such as dementia, Parkinson’s disease, substance and alcohol use disorders, ...

Aronne, MD, of Weill Cornell Medicine in New York City, made a compelling case that the next generation of obesity ...